What's New Since Our Last Report

We already covered the NEJM publication and the FDA's expanded access decision. On Sunday, May 31, 2026, Dr. Brian Wolpin of the Dana-Farber Cancer Institute formally presented the Phase 3 trial data to the oncology community at the ASCO annual meeting in Chicago. Unlike a journal publication, this meant the medical establishment saw the numbers in real time, with the researchers present to answer questions.

The Reaction in That Room

Dr. Rachna Shroff of the University of Arizona Cancer Center was in the audience and had no involvement in the study. According to AP News, she said: "Having treated pancreatic cancer for 16 years, I actually started crying" when she saw the results.

A doctor who has watched patients die repeatedly over nearly two decades was struck by data she didn't expect.

She zeroed in on something the headline numbers alone don't capture: patients stayed on this drug. Not because they were forced to. Because it was working. According to NPR, Shroff noted she was struck by how patients "stayed on this treatment because it was providing durable and meaningful benefit to them."

This is clinically significant. Patients dropping off treatment early is one of the biggest confounders in cancer trial data. Here, the opposite happened.

The Wolpin Declaration

Wolpin didn't hedge. According to CNBC, he said daraxonrasib "should become a new standard of care" for previously treated metastatic pancreatic cancer.

In oncology, that phrase carries weight. It means: if you're a doctor treating this disease and you're NOT offering this drug, you need a very good reason why.

He also flagged what comes next — researchers will explore whether early-stage use of the drug could shrink tumors enough to make patients surgical candidates. Surgery is currently the only path to potential cure for pancreatic cancer. Most patients never qualify. If daraxonrasib changes that math even for a fraction of patients, the implications are enormous.

The Survival Numbers — Keeping It Honest

The core data hasn't changed: 13.2 months median survival on daraxonrasib versus 6.7 months on chemotherapy, in 500 patients with metastatic pancreatic cancer that had stopped responding to prior treatment.

On the conventional coverage side, some outlets are softening a key detail: those are median numbers. Half the patients on daraxonrasib lived longer than 13.2 months. And Dr. Zev Wainberg of UCLA — who helped lead the study — told NPR the survival gap will likely widen. Why? Because many patients were still on the drug when the data was cut. The final numbers aren't in yet.

The headline number may be the floor, not the ceiling.

Side Effects — Don't Ignore This Part

According to Houston Public Media and CNBC, the two side effects most likely to cause patients to stop taking the drug are a potentially severe rash and mouth sores. Not life-threatening in most cases. But painful and quality-of-life-affecting.

This is not zero-consequence medicine. Patients and doctors need that conversation upfront.

The FDA Question Nobody Is Asking Loudly Enough

Revolution Medicines — the company that makes daraxonrasib and funded the study — has an expedited FDA review path. According to CNBC and Houston Public Media, the FDA plans to fast-track its review. Expanded access already exists for patients who meet certain criteria.

But "expedited" is relative. The FDA can still take months. Patients with metastatic pancreatic cancer often don't have months to spare.

Mainstream coverage has largely omitted one question entirely: what does this drug cost, and who pays for it? Revolution Medicines is a publicly traded company (RVMD on Nasdaq). They funded this trial. They will price this drug. The oncology world is celebrating a clinical win — the pricing conversation hasn't started publicly yet. It will. And it will matter to the 66,000 Americans diagnosed with pancreatic cancer every year.

What the Medical Establishment Just Signaled

The ASCO presentation is the moment the broader oncology community formally adopts or rejects a new treatment paradigm. When a Dana-Farber researcher presents the data and calls it a new standard of care — in front of thousands of oncologists — that's a signal to cancer centers nationwide to update their protocols.

This is the system working as intended.

Looking Ahead

The science is real. The emotion in that Chicago conference room was real. The survival gains are real — and may get larger as follow-up continues.

Now comes the hard part: getting the FDA to move fast, keeping the drug affordable enough that a 65-year-old in rural Texas has the same shot as a Silicon Valley executive, and making sure the expanded access program actually reaches patients who need it today — not next year.

The drug works. Whether the system around it will work is a different question entirely.